OPKO Health, Inc. (NASDAQ:OPK) Given Average Recommendation of “Hold” by Analysts

Shares of OPKO Health, Inc. (NASDAQ:OPK) have been given a consensus recommendation of “Hold” by the six brokerages that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, four have given a hold recommendation and one has given a strong buy recommendation to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $1.55.

Several equities analysts have recently issued reports on OPK shares. Wall Street Zen raised shares of OPKO Health from a “sell” rating to a “hold” rating in a research note on Saturday, June 6th. Weiss Ratings raised shares of OPKO Health from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, May 18th. Finally, Barrington Research cut shares of OPKO Health from an “outperform” rating to a “market perform” rating in a report on Wednesday, April 29th.

Hedge Funds Weigh In On OPKO Health

Hedge funds have recently modified their holdings of the stock. Goldman Sachs Group Inc. raised its position in shares of OPKO Health by 150.9% during the fourth quarter. Goldman Sachs Group Inc. now owns 5,986,913 shares of the biotechnology company’s stock worth $7,544,000 after purchasing an additional 3,600,378 shares during the period. Millennium Management LLC boosted its position in shares of OPKO Health by 39.2% in the 1st quarter. Millennium Management LLC now owns 6,386,911 shares of the biotechnology company’s stock valued at $10,602,000 after purchasing an additional 1,798,385 shares during the period. AQR Capital Management LLC increased its stake in OPKO Health by 466.7% in the 1st quarter. AQR Capital Management LLC now owns 1,608,906 shares of the biotechnology company’s stock worth $2,671,000 after purchasing an additional 1,324,988 shares in the last quarter. OP Asset Management Ltd acquired a new stake in OPKO Health during the 1st quarter worth about $1,257,000. Finally, HRT Financial LP acquired a new stake in OPKO Health during the 4th quarter worth about $851,000. 64.63% of the stock is currently owned by institutional investors and hedge funds.

OPKO Health Trading Up 2.0%

Shares of OPKO Health stock opened at $1.53 on Thursday. The company has a quick ratio of 3.17, a current ratio of 3.61 and a debt-to-equity ratio of 0.28. The firm has a market cap of $1.16 billion, a price-to-earnings ratio of -5.67 and a beta of 1.50. The business has a fifty day simple moving average of $1.31 and a 200-day simple moving average of $1.26. OPKO Health has a fifty-two week low of $0.98 and a fifty-two week high of $1.61.

OPKO Health (NASDAQ:OPK) last released its earnings results on Tuesday, April 28th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.07). OPKO Health had a negative return on equity of 16.78% and a negative net margin of 36.63%.The firm had revenue of $124.20 million for the quarter, compared to analyst estimates of $130.51 million. During the same period in the previous year, the company earned ($0.10) earnings per share. OPKO Health’s revenue was down 17.1% compared to the same quarter last year. On average, equities analysts forecast that OPKO Health will post -0.29 EPS for the current fiscal year.

About OPKO Health

OPKO Health, Inc (NASDAQ:OPK) is a diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development. The company operates two main business segments—Laboratory Services and Pharma Services & Products—driven by its mission to advance patient care through innovation in testing and targeted therapies.

In its Laboratory Services segment, OPKO leverages BioReference Laboratories, one of the largest full-service commercial labs in the United States.